Operative Unit of Neurology, S. Giovanni di Dio, Crotone, Italy.
Minerva Med. 2011 Apr;102(2):125-32.
Aim of the present study was to evaluate the clinical efficacy, tolerability and quality-of-life measures to melevodopa in advanced Parkinson's disease (PD) with motor fluctuations (MFs).
A total of 37 patients with advanced PD and MFs participated in the study. Patients were switched from standard l-dopa/carbidopa to melevodopa and were treated for 10 weeks.
Assessment of "On-Day" time demonstrated improvement to about 0.7 hour in the melevodopa treatment. The benefit was greater in patients with "delayed-on" (P=0.002) and especially in those with both "delayed-on" and "wearing-off" (P<0.001). Most patients showed a significant improvement in PDQ-39 total score (P=0.002) and PSI distress domain (P<0.001). Instead, not significant difference was observed in patients with only wearing-off.
These data show that melevodopa is an effective agent for improving daily motor performance and quality-of-life in PD with "delayed-on", also in association with "wearing-off".
本研究旨在评估美多芭治疗晚期帕金森病（PD）伴运动波动（MFs）的临床疗效、耐受性和生活质量措施。
共有 37 名晚期 PD 伴 MFs 的患者参与了这项研究。患者从标准左旋多巴/卡比多巴转换为美多芭，并接受了 10 周的治疗。
“开期”时间的评估显示，美多芭治疗后约有 0.7 小时的改善。对于“迟发性开期”（P=0.002），尤其是“迟发性开期”和“开期波动”（P<0.001）的患者，获益更大。大多数患者的 PDQ-39 总分（P=0.002）和 PSI 苦恼域（P<0.001）均有显著改善。而仅有开期波动的患者则没有观察到显著差异。
这些数据表明，美多芭是一种有效的药物，可改善伴有“迟发性开期”的 PD 患者的日常运动表现和生活质量，也可改善“开期波动”患者的生活质量。
